{"success":true,"data":{"pressRelease":{"id":"23359","rtpr_id":"nPn1NNmBya","ticker":"IBRX","exchange":"NASDAQ","all_tickers":["IBRX"],"title":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky","author":"PR Newswire","published_at":"2026-05-06T13:00:21.164Z","article_body":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky\n\nPR Newswire\n\nNEW YORK, May 6, 2026\n\nNotice to Pension Funds, Asset Managers, and Fiduciaries\n\nNEW YORK, May 6, 2026 /PRNewswire/ -- Institutional investors holding\npositions in ImmunityBio, Inc. (NASDAQ: IBRX) during the period January 19,\n2026 through March 24, 2026 may wish to evaluate lead plaintiff opportunities\nin a pending securities class action. Shares lost $1.98 per share, a 21%\ndecline, after an FDA Warning Letter exposed allegedly false promotional\nclaims about the Company's lead drug, ANKTIVA. Request an institutional\ninvestor loss assessment\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681714-13&h=2095697697&u=https%3A%2F%2Fzlk.com%2Fcases%2Fimmunitybio-inc-lawsuit-submission-form%3Fprid%3D185022%26wire%3D4&a=Request+an+institutional+investor+loss+assessment)\n or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com\n(mailto:jlevi@levikorsinsky.com)  or (212) 363-7500.\n\n(https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.html)\n\nThe window to apply for lead plaintiff closes on May 26, 2026. Portfolio\nmanagers, pension fund trustees, and other fiduciaries should assess whether\ntheir funds purchased IBRX securities at prices allegedly inflated by the\nExecutive Chairman's public misrepresentations regarding ANKTIVA's efficacy\nand approved uses.\n\nFiduciary Obligations and Recovery Options\n\nFiduciaries overseeing portfolios that held IBRX shares during the class\nperiod face distinct obligations under ERISA and applicable state law:\n\n * Pension funds and retirement plan trustees have a duty to investigate\npotential recoveries on behalf of beneficiaries when portfolio holdings are\naffected by alleged securities fraud\n * Institutional investors with the largest documented losses are best positioned\nto serve as lead plaintiff and direct case strategy\n * Lead plaintiff appointment carries no additional financial cost; counsel fees\nare contingent and court-approved\n * Serving as lead plaintiff provides direct oversight of settlement\nnegotiations, ensuring fiduciary interests are prioritized\n * Failure to evaluate recovery options may itself raise questions about prudent\nfiduciary management\nContact us for institutional recovery options\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681714-13&h=3271335309&u=https%3A%2F%2Fzlk.com%2Fcases%2Fimmunitybio-inc-lawsuit-submission-form%3Fprid%3D185022%26wire%3D4&a=Contact+us+for+institutional+recovery+options)\n or call (212) 363-7500.\n\nPortfolio Impact Assessment\n\nThe alleged misconduct centers on statements made by the Executive Chairman on\na nationally broadcast podcast on January 19, 2026, in which ANKTIVA was\ndescribed as a treatment that \"can treat all cancers\" while an on-screen\nbanner referred to it as a \"Cancer Therapeutic Vaccine.\" The FDA's subsequent\nWarning Letter, publicized March 24, 2026, determined these promotional\ncommunications were false or misleading and that ANKTIVA had been misbranded\nin violation of the FD&C Act. IBRX shares closed at $7.42 on March 24,\n2026, down from $9.40 the prior session.\n\nFor institutional holders with concentrated biotech or healthcare allocations,\nthe loss may represent a material portfolio event requiring documentation and\nreporting.\n\nCase Summary\n\nThe securities action alleges violations of Sections 10(b) and 20(a) of the\nExchange Act. The complaint contends that the Company's promotional materials\ngrossly overstated ANKTIVA's therapeutic scope, claiming efficacy across \"all\ncancers\" and describing an unapproved subcutaneous route of administration,\nwhen the drug is approved only for intravesical use in a specific type of\nbladder cancer. ANKTIVA's clinical trial showed a 62% complete response rate\nin 77 patients with BCG-unresponsive NMIBC, and the single-agent cohort was\nstopped early for futility.\n\n\"Institutional investors play a critical role in securities class actions.\nTheir participation as lead plaintiff ensures that cases are prosecuted with\nthe rigor and resources the class deserves, and that fiduciary interests are\nrepresented at the highest level.\" -- Joseph E. Levi, Esq.\n\nAbout Levi & Korsinsky, LLP\n\nINSTITUTIONAL INVESTOR REPRESENTATION -- Levi & Korsinsky, LLP provides\nsophisticated counsel to institutional investors evaluating lead plaintiff\nopportunities. The firm has recovered hundreds of millions of dollars. Ranked\namong ISS Top 50 for seven consecutive years.\n\nFrequently Asked Questions About the IBRX Lawsuit\n\nQ: Who is eligible to join the IBRX investor lawsuit? A: Investors who\npurchased IBRX stock or securities between January 19, 2026 and March 24, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses, not on whether you still hold the shares.\n\nQ: What is the IBRX lead plaintiff deadline? A: The deadline to apply for\nlead plaintiff appointment is May 26, 2026. This deadline applies only to\ninvestors seeking to serve as lead plaintiff. Class members who do not apply\nmay still participate in any recovery without taking action before this date.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I already sold my IBRX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: What documents do I need to make a claim? A: Brokerage statements or trade\nconfirmations showing purchase dates, share quantities, prices paid, and any\nsubsequent sale dates and prices.\n\nQ: Can I join a different law firm's lawsuit instead? A: Multiple firms often\nfile competing complaints. The court consolidates and appoints a single lead\ncounsel. Contacting Levi & Korsinsky before May 26, 2026 ensures your\nlosses are considered.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)\nTel: (212) 363-7500\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ibrx-investor-alert-immunitybio-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-chairman-allegedly-misbranded-cancer-drug-levi--korsinsky-302763598.html\n(https://www.prnewswire.com/news-releases/ibrx-investor-alert-immunitybio-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-chairman-allegedly-misbranded-cancer-drug-levi--korsinsky-302763598.html)\n\nSOURCE Levi & Korsinsky, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1NNmBya","title":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky","author":"PR Newswire","ticker":"IBRX","created":"2026-05-06T13:00:21.164Z","tickers":["IBRX"],"exchange":"NASDAQ","article_body":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky\n\nPR Newswire\n\nNEW YORK, May 6, 2026\n\nNotice to Pension Funds, Asset Managers, and Fiduciaries\n\nNEW YORK, May 6, 2026 /PRNewswire/ -- Institutional investors holding\npositions in ImmunityBio, Inc. (NASDAQ: IBRX) during the period January 19,\n2026 through March 24, 2026 may wish to evaluate lead plaintiff opportunities\nin a pending securities class action. Shares lost $1.98 per share, a 21%\ndecline, after an FDA Warning Letter exposed allegedly false promotional\nclaims about the Company's lead drug, ANKTIVA. Request an institutional\ninvestor loss assessment\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681714-13&h=2095697697&u=https%3A%2F%2Fzlk.com%2Fcases%2Fimmunitybio-inc-lawsuit-submission-form%3Fprid%3D185022%26wire%3D4&a=Request+an+institutional+investor+loss+assessment)\n or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com\n(mailto:jlevi@levikorsinsky.com)  or (212) 363-7500.\n\n(https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.html)\n\nThe window to apply for lead plaintiff closes on May 26, 2026. Portfolio\nmanagers, pension fund trustees, and other fiduciaries should assess whether\ntheir funds purchased IBRX securities at prices allegedly inflated by the\nExecutive Chairman's public misrepresentations regarding ANKTIVA's efficacy\nand approved uses.\n\nFiduciary Obligations and Recovery Options\n\nFiduciaries overseeing portfolios that held IBRX shares during the class\nperiod face distinct obligations under ERISA and applicable state law:\n\n * Pension funds and retirement plan trustees have a duty to investigate\npotential recoveries on behalf of beneficiaries when portfolio holdings are\naffected by alleged securities fraud\n * Institutional investors with the largest documented losses are best positioned\nto serve as lead plaintiff and direct case strategy\n * Lead plaintiff appointment carries no additional financial cost; counsel fees\nare contingent and court-approved\n * Serving as lead plaintiff provides direct oversight of settlement\nnegotiations, ensuring fiduciary interests are prioritized\n * Failure to evaluate recovery options may itself raise questions about prudent\nfiduciary management\nContact us for institutional recovery options\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681714-13&h=3271335309&u=https%3A%2F%2Fzlk.com%2Fcases%2Fimmunitybio-inc-lawsuit-submission-form%3Fprid%3D185022%26wire%3D4&a=Contact+us+for+institutional+recovery+options)\n or call (212) 363-7500.\n\nPortfolio Impact Assessment\n\nThe alleged misconduct centers on statements made by the Executive Chairman on\na nationally broadcast podcast on January 19, 2026, in which ANKTIVA was\ndescribed as a treatment that \"can treat all cancers\" while an on-screen\nbanner referred to it as a \"Cancer Therapeutic Vaccine.\" The FDA's subsequent\nWarning Letter, publicized March 24, 2026, determined these promotional\ncommunications were false or misleading and that ANKTIVA had been misbranded\nin violation of the FD&C Act. IBRX shares closed at $7.42 on March 24,\n2026, down from $9.40 the prior session.\n\nFor institutional holders with concentrated biotech or healthcare allocations,\nthe loss may represent a material portfolio event requiring documentation and\nreporting.\n\nCase Summary\n\nThe securities action alleges violations of Sections 10(b) and 20(a) of the\nExchange Act. The complaint contends that the Company's promotional materials\ngrossly overstated ANKTIVA's therapeutic scope, claiming efficacy across \"all\ncancers\" and describing an unapproved subcutaneous route of administration,\nwhen the drug is approved only for intravesical use in a specific type of\nbladder cancer. ANKTIVA's clinical trial showed a 62% complete response rate\nin 77 patients with BCG-unresponsive NMIBC, and the single-agent cohort was\nstopped early for futility.\n\n\"Institutional investors play a critical role in securities class actions.\nTheir participation as lead plaintiff ensures that cases are prosecuted with\nthe rigor and resources the class deserves, and that fiduciary interests are\nrepresented at the highest level.\" -- Joseph E. Levi, Esq.\n\nAbout Levi & Korsinsky, LLP\n\nINSTITUTIONAL INVESTOR REPRESENTATION -- Levi & Korsinsky, LLP provides\nsophisticated counsel to institutional investors evaluating lead plaintiff\nopportunities. The firm has recovered hundreds of millions of dollars. Ranked\namong ISS Top 50 for seven consecutive years.\n\nFrequently Asked Questions About the IBRX Lawsuit\n\nQ: Who is eligible to join the IBRX investor lawsuit? A: Investors who\npurchased IBRX stock or securities between January 19, 2026 and March 24, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses, not on whether you still hold the shares.\n\nQ: What is the IBRX lead plaintiff deadline? A: The deadline to apply for\nlead plaintiff appointment is May 26, 2026. This deadline applies only to\ninvestors seeking to serve as lead plaintiff. Class members who do not apply\nmay still participate in any recovery without taking action before this date.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I already sold my IBRX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: What documents do I need to make a claim? A: Brokerage statements or trade\nconfirmations showing purchase dates, share quantities, prices paid, and any\nsubsequent sale dates and prices.\n\nQ: Can I join a different law firm's lawsuit instead? A: Multiple firms often\nfile competing complaints. The court consolidates and appoints a single lead\ncounsel. Contacting Levi & Korsinsky before May 26, 2026 ensures your\nlosses are considered.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)\nTel: (212) 363-7500\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ibrx-investor-alert-immunitybio-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-chairman-allegedly-misbranded-cancer-drug-levi--korsinsky-302763598.html\n(https://www.prnewswire.com/news-releases/ibrx-investor-alert-immunitybio-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-chairman-allegedly-misbranded-cancer-drug-levi--korsinsky-302763598.html)\n\nSOURCE Levi & Korsinsky, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-06T13:00:21.228523181Z","server_sent_at_ms":1778072421228},"received_at":"2026-05-06T13:00:21.281Z","source_url":null},"analysis":{"id":"18144","press_release_id":"23359","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Levi & Korsinsky is soliciting institutional investors to serve as lead plaintiff in a class action against ImmunityBio regarding alleged securities fraud and misbranding of drug ANKTIVA.\n\nThe lawsuit concerns the period between January and March 2026, citing a 21% share decline following an FDA Warning Letter about false promotional claims.\n\nThis is a plaintiff law firm announcement; the deadline to apply for lead plaintiff is May 26, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Institutional investors play a critical role in securities class actions. Their participation as lead plaintiff ensures that cases are prosecuted with the rigor and resources the class deserves, and that fiduciary interests are represented at the highest level.","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Partner/Attorney at Levi & Korsinsky, LLP"},{"name":"Ed Korsinsky","role":"Partner/Attorney at Levi & Korsinsky, LLP"}],"products":["ANKTIVA"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1.98 per share","context":"share loss during class period"},{"amount":"$7.42","context":"IBRX closing price on March 24, 2026"},{"amount":"$9.40","context":"IBRX closing price on prior session"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Levi & Korsinsky. No new disclosure from the issuer; no certified class or settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"IBRX"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky is soliciting institutional investors to serve as lead plaintiff in a class action against ImmunityBio regarding alleged securities fraud and misbranding of drug ANKTIVA.\n\nThe lawsuit concerns the period between January and March 2026, citing a 21% share decline following an FDA Warning Letter about false promotional claims.\n\nThis is a plaintiff law firm announcement; the deadline to apply for lead plaintiff is May 26, 2026.","key_figures":{},"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Partner/Attorney at Levi & Korsinsky, LLP"},{"name":"Ed Korsinsky","role":"Partner/Attorney at Levi & Korsinsky, LLP"}],"products":["ANKTIVA"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1.98 per share","context":"share loss during class period"},{"amount":"$7.42","context":"IBRX closing price on March 24, 2026"},{"amount":"$9.40","context":"IBRX closing price on prior session"}]},"model_name":"glm-4.7","prompt_hash":"sha256:6c7fa2f5e3b62e83","schema_hash":"sha256:ee8f711bc9bfba0d","created_at":"2026-05-07T00:04:30.597Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small/mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":null,"modelName":"glm-4.7"}}